Groups
Company Size (Fulltime employees)
Partnering Objectives
Functionality
Headquartner in China
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Medtech Category
Medtech Development Stage
Index
Countries
Reset

china medical city China

Mainly for investment services and project indUnited Statestrialization
Website:
www.cmc.com
Partnering Objectives
Headquartner in China
Yes
Biotech/Pharma Category
敏 刘
副局长 
琳琳 武
副部长 

China医药创新促进会 China

China医药创新促进会（原名“China医药工业科研开发促进会”,简称“China药促会”）,英文名称：China Pharmaceutical Innovation and Research Development Association（PhIRDA）,成立于1988年,是经国家民政部登记注册的非营利性全国性4A级社会组织。
China药促会秉承“创新、产业化、国际化”的宗旨,以临床需求为导向,长期致力于“产学研用资”紧密结合,促进医药行业创新发展,已经成为集医药创新研发型企业、科研机构、临床研究机构、创新服务机构和医药投资机构所组成的医药创新产业化促进平台,目前有会员单位144家。China药促会已成立了药物研发专业委员会、药物临床研究专业委员会、医药政策专业委员会、医药创新投资专业委员会和创新研发服务专业委员会,形成了以创新为核心,以促进创新为目标的涵盖药物研发、生产、使用以及投融资的全链条组织构架,并作为国际药品制造商协会联合会（IFPMA）的成员继续拓展国际交流渠道。
Website:
www.phirda.com
Partnering Objectives
Headquartner in China
Yes
Biotech/Pharma Category
根 李
国际部项目主管 

CureMeta United States

CureMeta is a therapeutic oncology biotech with the mission to develop therapeutic antibodies to novel cancer targets that are present in aggressive cancers and to develop new powerful cancer drugs to provide meaningful treatments and cures for patients with metastatic cancer.

We are seeking partners to out-license our lead therapeutic: CM-09, a first in class Antibody-Drug-Conjuate for gastric cancers.

Website:
CureMeta.com
Company Size (Fulltime employees)
1-10
Year of foundation
2012
Partnering Objectives
Headquartner in China
No
Biotech/Pharma Category
Assets Information 1
CM-09, a first-in-class Antibody-Drug-Conjugate for gastric and pancreatic cancers. US patent awarded, patent filed in China, Japan, South Korea, Russian, Australia, India, Brazil and Europe.
Slides Deck
(pdf, 2.95MB)
Dr. MIke Schopperle
CSO 

Cytovance Biologics United States

Cytovance® Biologics is a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO) that excels in the rapid and cost-effective development and manufacture of large molecule APIs from both mammalian cell culture and microbial fermentation such as monoclonal antibodies, fragment antibodies, bispecifics, enzymes, fusion proteins, vaccines and other biological products including plasmid DNA and cell-based therapeutics. In addition to our clinical and commercial cGMP API manufacturing services, Cytovance offers well integrated development services supporting the entire product lifecycle including cell line development, cell banking, microbial strain development, process and analytical development, and process characterization. A centralized, responsive program management team coordinates all critical CMC activities for each client program around raw materials management, QC testing, ICH stability studies, and regulatory support. Our 140,000 sq. ft. state-of-the-art facilities in Oklahoma City are designed to meet U.S., EU, and other global regulatory standards.
Website:
www.cytovance.com
Company Size (Fulltime employees)
201-500
Year of foundation
2005
Partnering Objectives
Please specify your partnering goal
TBD
Headquartner in China
No
Biotech/Pharma Category
Mr. Matt Delaney
VP of Business Development and Marketing 
Functionality
Business Development

D3 BIO

Website:
www.d3bio.com
Partnering Objectives
Biotech/Pharma Category
Dr John Jin
Dr John Jin
Co-founder & CBO 
Functionality
Business Development
John Jin
Co-founder&CBO 

Dao Tun GmbH Switzerland

Dao Tun is a consulting company, founded in 2019, specialised in cross-border collaboration between Europe and China, primarily in the healthcare and life science industry.
Dao Tun is based in the Basel region, one of the world's leading clusters for Pharma and Life Sciences and also part of the trinational Biovalley region (Switzerland, Germany, France).
Dao Tun team provides customised strategy and execution plan via in-depth interview and targeted research; quickly gains insights into the association and matching between potential partners to make accurate and effective connections; simplifies the processes, reduces the cost of communication, and establishes the trust with full care.
Dao Tun is a bridge builder who excels at understanding and interpreting their interests and needs, and aligning perspectives of different stakeholders and across cultures for win-win-win situation.

Website:
www.dao-tun.ch
Company Size (Fulltime employees)
1-10
Year of foundation
2019
Partnering Objectives
Please specify your partnering goal
looking for clients and partners who have interest to enter Chinese market for fundraising, licensing, partnering etc.
Headquartner in China
No
Biotech/Pharma Category
Medtech Category
Dr. Tianke Wang
Dr. Tianke Wang
CEO 
Functionality
Management

DHVC United States

Life Science and Healthcare Venture Capital Investor
Website:
www.dh.vc
Company Size (Fulltime employees)
1-10
Year of foundation
2013
Partnering Objectives
Please specify your partnering goal
Investment
Headquartner in China
No
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Medtech Category
Medtech Development Stage
Ali Farahanchi
Managing Director 
Functionality
Investment

Duality Biologics China

Duality Biologics is a China biotech company focusing on the discovery, development and commercialization of new modality biologics to provide solutions to unmet medical needs for grievous diseases in Great China area. Backed by proprietary new modality platform ensuring fast biological validation and development, Duality Biologics has been building a combined pipeline of First-in-class and Best-in-class. Currently, Duality seeks for licensing-in opportunities in broad disease areas especially oncology and autoimmune diseases
Website:
N/A
Company Size (Fulltime employees)
11-50
Partnering Objectives
Please specify your partnering goal
Clinical stage assets in oncology and immunology
Headquartner in China
Yes
Biotech/Pharma Category
Dr. John Zhu
Founder and CEO 
Functionality
Management

Elasmogen Ltd United Kingdom

Elasmogen, a next generation biologics company, develops soloMERs which are high affinity binding, single-domains; they are small (9% of an antibody), highly stable proteins and crucially are outside the complex/competitive antibody patent landscape. soloMERs are pre-disposed to generating potent neutralisers by binding to novel or cryptic epitopes. Their small size makes them ideal for both site-specific delivery and penetration of solid tumours. Our lead product, ADCP165, is an anti-ROR1 soloMER drug conjugate being co-developed with Almac Discovery. This program is tracking for entry into the clinic 2022/3 with follow on products in the pipeline. In addition our lead anti-auto-immune inflammatory domain, ELN/22, a tetravalent, bi-paratopic anti-TNF product is being developed for oral delivery for the treatment of IBD.
We are currently looking for partners for our existing assets and also companies who would like to access our powerful, patent protected soloMER platform to develop new products.
Website:
www.elasmogen.com
Company Size (Fulltime employees)
10-Jan
Year of foundation
2016
Partnering Objectives
Please specify your partnering goal
Licensing of existing assets and co-development of new therapeutic development
Headquartner in China
No
Biotech/Pharma Category
Dr. Caroline Barelle
CEO 
Functionality
Research and Development

Enbao asset China

Private equity investment institutions in the secondary market, focusing on pharmaceutical consumption and other industries
Website:
NA
Company Size (Fulltime employees)
1-10
Year of foundation
2014
Partnering Objectives
Please specify your partnering goal
NA
Headquartner in China
Yes
Biotech/Pharma Category
Mr. Zongde Pan
Investment anlyst 
Functionality
Investment